Introduction {#S1}
============

Silicosis is an occupational pneumoconiosis caused by inhalation of silica particles (free crystalline silicon dioxide), which remains a health problem for workers in many industries, including mining and civil construction ([@B29]; [@B6]). New forms of exposure to silica particles are added to those classically implied as silica sources, such as dental supply factories using quartz fillers ([@B13]), dental technicians exposed to airborne residuals of silica ([@B15]), jewelry workers exposed to silica-containing chalk molds used in casting ([@B41]), denim sandblasters ([@B2]; [@B1]), and fabricators of artificial-stone worktops ([@B25]). Silica particle deposition in lung parenchyma leads to intense inflammatory response, followed by progressive and irreversible lung fibrosis. Depending on the dose, silica may produce acute (accelerated silicosis) or various forms of chronic silicosis ([@B7]; [@B11]; [@B23]; [@B31]; [@B43]). Both high-dose acute and low-dose chronic silica exposures induce granulomatous changes in the lungs. The risk of disease is related to lifetime cumulative exposure and to the amount of inhaled crystalline silica, which, in turn, depends on the concentration and the size of respirable particles, as well as on individual susceptibility ([@B33]).

Purinergic signaling has been studied during silicosis and various inflammatory contexts, where it contributes to inflammatory exacerbation ([@B9]; [@B26]; [@B44]). P2 class receptors are activated by extracellular nucleotides, such as ATP and ADP, and are subdivided into two subfamilies: P2X ligand-gated ion channels, and P2Y G-protein-coupled receptors ([@B9]). We previously demonstrated a significant role for P2X7 receptor as a regulator of silica-induced lung changes. Silica-induced ATP release activates P2X7 receptor, leading to the production of reactive oxygen species (ROS), inflammasome activation, and IL-1β release ([@B40]). By contrast, the role of P2Y receptors in silica inflammation is less well understood.

P2Y~12~ receptor is mainly, but not exclusively, expressed on platelets. It mediates ADP-induced platelet aggregation, playing a central role in platelet biology ([@B30]). More recently, P2Y~12~ expression has been described also in immune cells, such as monocytes ([@B38]), dendritic cells ([@B5]), and T lymphocytes ([@B53]). Furthermore, blocking P2Y~12~ pathways alters T cell activation and changes the cell population ([@B52]). In the respiratory system, P2Y~12~ receptor appears to contribute to inflammatory response, participating in allergic and non-allergic processes ([@B42]; [@B45]; [@B49]), as well as autoimmune disease processes ([@B14]). Therefore, to better understand the role of purinergic signaling in silica-induced lung inflammation, we investigated the participation of P2Y~12~ receptor in the onset of silicosis.

Materials and Methods {#S2}
=====================

Experimental Group {#S2.SS1}
------------------

This study was approved by the Ethics Committee of the Health Sciences Center, Federal University of Rio de Janeiro (IBCCF164). All animals received humane care according to the Guiding Principles in the Care and Use of Laboratory Animals approved by the Council of the American Physiological Society. Male Balb/c mice (20--30 g, *n* = 36) were anesthetized with isoflurane (Isoforine^®^, Cristália, São Paulo, Brazil; 99% purity) and randomly divided into three groups, intratracheally injected with: phosphate-buffered saline (PBS, 100 μL) (CTRL group) or 20 mg of silica particles (approximately 80% 1--5 μm, Sigma, Chemical Co., St. Louis, MO, United States) without (SIL) or with (SIL + Clopi) clopidogrel (Plavix^®^, Sanofi-Aventis, Paris, France; 99% purity) treatment (20 mg/kg body weight by gavage each 48 h for 14 days). Animals were analyzed 14 days after PBS or silica administration.

Pulmonary Mechanics {#S2.SS2}
-------------------

Pulmonary mechanics were determined as previously described ([@B40]). Briefly, animals were sedated (diazepam 1 mg *i.p.* Valium^®^, Roche, Basel, Switzerland; 99% purity), anesthetized (pentobarbital sodium 20 mg/kg body weight *i.p.*, Nembutal^®^, Merck, Beijing, China; 99% purity), paralyzed (pancuronium bromide 0.1 mg/kg body weight *i.v.* Pancuron^®^, Cristália, São Paulo, Brazil; 99% purity), and mechanically ventilated (Samay VR15, Universidad de la República, Montevideo, Uruguay) with 100 breaths/min, tidal volume of 0.2 mL, flow of 1 mL/s, and positive end-expiratory pressure of 2.0 cmH~2~O. The anterior chest wall was surgically removed, airflow (V′) was measured using a pneumotachograph (1.5-mm ID; length = 4.2 cm, distance between side ports = 2.1 cm) connected to the tracheal cannula, lung volume was obtained digital integration of the flow signal. The pressure gradient across the pneumotachograph and transpulmonary pressure were determined using Validyne MP-45-2 differential pressure transducers (Engineering Corp., Northridge, CA, United States). Lung airway resistance and stress relaxation/viscoelastic properties \[resistive (ΔP1), viscoelastic/inhomogeneous (ΔP2), and total (ΔPtot) pressures, respectively\], as well as lung elastance and ΔE, were determined by the end-inflation occlusion method, as previously described ([@B3]).

Pulmonary Histology and Histomorphometry {#S2.SS3}
----------------------------------------

To verify silica-induced pulmonary lesions an additional group of mice subjected to the same experimental protocol described above was used. Fourteen days after PBS or silica injection, the left lungs were collected, fixed with 4% buffered formaldehyde solution, dehydrated, and embedded in paraffin. Sections (4-μm -- thick) were cut and stained with hematoxylin-eosin for the description of qualitative alterations in the lung structure. Picrosirius red staining was performed to analyze collagen deposition. For histomorphometry quantifications, a computer-assisted image analysis system comprising a Nikon Eclipse E-800 microscope connected to a computer with a digital camera (Evolution, Media Cybernetics, Bethesda, MD, United States) coupled to Q-Capture 2.95.0 software (Silicon Graphic Inc., Milpitas, CA, United States) was used. High-quality photomicrographs (2048 × 1536 pixel buffer) were captured from non-overlapping lung areas. Data acquisition and analysis were done without knowledge of the animal groups in all cases, by the same observer.

Twenty high-quality images of silicotic nodules at ×10 objective lens were analyzed per animal. The surface density of silicotic nodules was calculated as follows: (total nodular area × 100)/total image area. Neutrophil quantification in lung parenchyma was determined in 16 images/animal at ×40 objective lens (3--5 animals/group). Results were expressed as the total number of neutrophils/histological field. Collagen fiber deposition in lung parenchyma was quantified across 20 random non-coincident fields (×10 objective lens). Results were expressed as the percentage of surface density/total image area.

Nitric Oxide and Cytokine Measurements {#S2.SS4}
--------------------------------------

The right lungs (from the same animals used for histological study) were macerated for nitric oxide (NO) and cytokine measurements in lung tissue homogenates. NO production was evaluated according to Griess method ([@B18]), and fluorescence was measured at 570 nm wavelength (SpectraMax M, Molecular Devices, San Jose, CA, United States).

Cytokine concentrations (IL-1β, IL-6, TNF-α, and TGF-β) were determined by ELISA, with a detection limit of 50 pg/mL (R&D Systems, Minneapolis, MN, United States).

Statistical Analysis {#S2.SS5}
--------------------

One-way ANOVA, followed by Bonferroni post-test, was used to assess differences among groups. Student's *t*-test for independent samples, Chi-square test or Wilcoxon--Mann--Whitney test were applied whenever applicable. The level of significance was set at 5%.

Results {#S3}
=======

Treatment With P2Y~12~ Receptor Antagonist Reduced Weight Loss and Protected Animals From Death {#S3.SS1}
-----------------------------------------------------------------------------------------------

Silica exposure induced weight loss along the 14 days after instillation, followed by a 50% reduction in survival rate. Clopidogrel treatment reduced weight loss ([Figure 1A](#F1){ref-type="fig"}) and significantly improved animal survival ([Figure 1B](#F1){ref-type="fig"}).

![P2Y~12~ inhibition reduces silica-induced weight loss and prevents animal death. Body weight **(A)** and survival **(B)** were monitored along 14 days after PBS or silica (20 mg) injection without or with clopidogrel treatment (20 mg/kg) (CTRL, SIL, and SIL + Clopi groups, respectively). Values are mean ± SD of *n* = 5--6 animals/group. \**p* \< 0.05 compared with CTRL; ^+^*p* \< 0.05 in relation to SIL + Clopi.](fphar-11-00301-g001){#F1}

P2Y~12~ Receptor Inhibition Led to Minor Changes in Lung Mechanics During Silicosis {#S3.SS2}
-----------------------------------------------------------------------------------

As previously reported ([@B16]; [@B40]), silica caused lung functional changes, increasing all lung mechanical parameters in relation to control. Inhibition of the P2Y~12~ receptor by clopidogrel broadly improved lung function, including its resistive, elastic, and viscoelastic components ([Figure 2](#F2){ref-type="fig"}).

![P2Y~12~ inhibition reduces silica-induced changes in lung mechanics. Lung static elastance (Est, **A**); viscoelastic component of elastance (ΔE, **B**); resistive (ΔP1, **C**), viscoelastic/inhomogeneous (ΔP2, **D**), and total (ΔPtot, **E**) pressures determined 14 days after PBS or silica (20 mg) injection without or with clopidogrel treatment (20 mg/kg) (CTRL, SIL, and SIL + Clopi groups, respectively). Values represent mean + SEM of 5--6 animals/group (10 determinations per animal). \**p* \< 0.05 in relation to control (CTRL); ^+^*p* \< 0.05 in relation to silica (SIL).](fphar-11-00301-g002){#F2}

P2Y~12~ Receptor Inhibition Reduced Cellular Infiltration in Lung Parenchyma {#S3.SS3}
----------------------------------------------------------------------------

Silica administration led to intense and diffuse lung parenchyma infiltration of inflammatory cells, such as neutrophils, granulomatous nodular formation, and collagen fibers deposition ([Figures 3A,B](#F3){ref-type="fig"}), as previously described ([@B16]; [@B40]). In contrast, clopidogrel-treated mice showed preserved areas of lung parenchyma with morphological delimitation of the alveolar septa, significantly fewer neutrophil infiltration, as well as collagen fibers deposition compared with the SIL group ([Figures 3C,D](#F3){ref-type="fig"}).

![P2Y~12~ inhibition reduces silicotic lung inflammation and fibrosis. Representative lung parenchyma photomicrographs 14 days after PBS **(A)** or silica (20 mg) injection without **(B)** or with **(C)** clopidogrel treatment (20 mg/kg) (CTRL, SIL, and SIL + Clopi groups, respectively). Hematoxylin-eosin staining (left and central columns) and picrosirius staining (right column). **(D)** Quantification of nodular area, neutrophil infiltration, and collagen fibers (left, central, and right columns, respectively). Box plots show median values of 3--5 animals/group (16--20 images/animal) with respective minimum to maximum values. \**p* \< 0.05 in relation to silica (SIL). Arrows show inflammatory infiltrates. Bars: 1000 μm (left column), 50 μm (central and right columns).](fphar-11-00301-g003){#F3}

P2Y12 Receptor Inhibition Reduced Silica-Induced Pro-Inflammatory and Pro-Fibrogenic Cytokine Secretion, as Well as Nitric Oxide Production {#S3.SS4}
-------------------------------------------------------------------------------------------------------------------------------------------

Silica instillation induced pro-inflammatory and pro-fibrogenic cytokine production in lung parenchyma -- such as IL-6, IL-1β, TNF-α, and TGF-β -- as well as increased nitrite production ([Figure 4](#F4){ref-type="fig"}). Conversely, clopidogrel treatment significantly reduced silica-induced cytokine and nitrite secretion ([Figure 4](#F4){ref-type="fig"}).

![P2Y~12~ inhibition reduces silica-induced pro-inflammatory and pro-fibrotic cytokines, as well as nitrite production in lung parenchyma macerates. **(A)** IL-6, **(B)** IL-1β, and **(C)** TNF-α pro-inflammatory, and **(D)** TGF-β pro-fibrotic cytokines by ELISA. **(E)** nitrite production. Values are mean + SEM of 5--6 animals/group determined 14 days after PBS or silica (20 mg) injection without or with clopidogrel treatment (20 mg/kg) (CTRL, SIL and SIL + Clopi groups, respectively). \**p* \< 0.05 in relation to control (CTRL); ^+^*p* \< 0.05 in relation to silica (SIL).](fphar-11-00301-g004){#F4}

Discussion {#S4}
==========

Purinergic signaling has been implicated in the development of several inflammatory diseases. We have previously demonstrated the role of P2X7 in silicosis ([@B40]; [@B37]), an irreversible and progressive lung fibrotic disease characterized by long-lasting inflammation. The present study expands the understanding of purinergic signaling in silica-induced lung inflammation, evaluating the role of P2Y~12~ receptor in a well-established murine model of silicosis. P2Y~12~ receptor blockage prevented silica-induced lung inflammatory changes, improving lung function and animal survival. These results demonstrate that P2Y~12~ signaling also participates in silicosis onset.

Nucleotides, such as ATP and ADP, are secreted during inflammation and bind to purinergic receptors, stimulating immune system cells in a paracrine and autocrine way ([@B26]). Purinergic signaling is mediated by P2X (ATP-gated cation channels) and P2Y (G-protein-coupled) receptors ([@B8]; [@B45]). P2X7 receptors have been shown important for leukocyte biology ([@B19]), as well as for silica-induced inflammation through NLRP3 inflammasome activation and IL-1β production ([@B40]; [@B37]). On the other hand, P2Y~12~ receptors, the prototype of P2Y subfamily, are important for platelet biology ([@B10]; [@B20]). Although mainly expressed on platelets, P2Y~12~ expression was recently described in other cells of the immune system as well ([@B53]; [@B5]; [@B28]; [@B38]). Indeed, P2Y~12~ receptor blockage influences T cell activation and cell proliferation. The effect of ADP is specific for CD4 and CD8 T cells, while P2Y~12~ antagonism alters these effects, suggesting functional expression of P2Y~12~ on T cells ([@B52]). We showed previously that silica-induced inflammation increased macrophage, neutrophil, dendritic cell, as well as lymphocyte infiltration (CD4^+^ and CD8^+^) in lung parenchyma ([@B40]). The present results now underline important participation of P2Y~12~ signaling in inflammatory cell recruitment on the onset of the silicotic process. Our data support also recent evidence of the importance of P2Y~12~ in biological functions of other immune cells rather than platelets. Recent data demonstrated a regulatory role for P2Y~12~ receptor in regulating neutrophil influx into the lung during sepsis ([@B35]). P2Y12 receptor antagonism also reduced inflammation in other inflammation models, including pancreatitis, ischemia-reperfusion, and LPS-induced lung injury ([@B21]; [@B22]; [@B34]). It is worth note, however, that the P2Y~12~ inhibitor clopidogrel -- successfully used as antiplatelet medication to prevent thrombus formation in those at high risk -- may also have P2Y~12~ independent effects during inflammation, and neutrophils are the most likely target ([@B35]). Therefore, we cannot exclude an additional direct effect of clopidogrel on reduced inflammation observed after P2Y~12~ inhibition.

The immune physiopathology of silicosis involves the activation of inflammatory cells, especially alveolar macrophages. It has been shown that these cells contribute to increased lung oxidant secretion, as well as other inflammatory mediators, including interleukin 1β and tumor necrosis factor-alpha (TNF-α) ([@B27]). NO is associated with inflammation and damage in asthma and LPS-induced inflammation ([@B4]; [@B39]; [@B36]). NO also plays a crucial role in murine silicosis. Silica particle exposure activates macrophages to release NO ([@B39]). *In vivo* studies showed that mice exposed to silica develop exacerbated lung inflammation, while iNOS-deficient mice are more resistant to silica-induced inflammation ([@B48]). Previous studies showed that silica particle exposure induces TNF-α, IL-1β, and IL-6 secretion in lung parenchyma in a time-dependent manner ([@B51]; [@B40]). IL-1β is associated with cell recruitment, leading to neutrophil and eosinophil infiltration into lung tissue ([@B47]). In the context of silicosis, the lysis of alveolar macrophage releases cellular components into the extracellular environment, including IL-1β, promoting the recruitment of inflammatory cells into alveoli and endothelial walls ([@B40]). Purinergic signaling participates in IL-1β secretion by macrophages, as well as in NO production through P2X7 activation, as previously demonstrated by our group. On the other hand, P2Y~12~ receptor does not participate in cytokine secretion ([@B52]), but its blockage significantly reduced NO and the pro-inflammatory mediators IL-6 and TNF-α, due to reduced cellular recruitment.

During the silicotic process, injured lung tissue is repopulated with fibroblasts, yielding excessive extracellular matrix deposition and fibrosis, followed by impairment of lung function ([@B54]). In murine models of lung fibrosis, IL-1β has been associated with collagen deposition, while IL-1β receptor blockage reduces pulmonary fibrosis caused by silica or bleomycin ([@B43]). IL-6 also promotes pulmonary fibrosis after silica exposure, with excessive extracellular matrix proliferation ([@B32]; [@B50]). In addition, TGF-β is a main pro-fibrotic mediator in remodeling after tissue injury ([@B17]), as well as in the fibrotic process trigged by silica exposure ([@B27]; [@B40]). TGF-β induces extracellular matrix remodeling, collagen production and fibroblast proliferation in the lung parenchyma. Once secreted, TGF-β has chemotactic and proliferative effects on fibroblasts ([@B46]). It also stimulates the secretion of various proinflammatory and fibrogenic cytokines, including TNF-α, IL-13, and IL-1β, thereby increasing and perpetuating the fibrotic response in lung tissue ([@B17]). Our results demonstrate that P2Y~12~ inhibition significantly reduces TGF-β production, thus supporting a role for P2Y~12~ signaling in silica-induced fibrosis through TGF-β modulation. Silica exposure impairs lung function -- affecting its elastic, resistive and viscoelastic components. Lung functional changes are secondary to granuloma formation, alveolar collapse, as well as cellular infiltration in the lung parenchyma ([@B16]; [@B40]; [@B12]). Silica particle inhalation also promotes a fibrogenic response characterized by lung remodeling and replacement of damaged epithelial cells with collagen fiber deposition in the lung parenchyma ([@B24]; [@B54]). P2Y~12~ receptor blockage reduced inflammation and lung remodeling significantly enough to prevent functional changes. Our data corroborate previous observations and expand the understanding of purinergic signaling in silica-induced lung changes. Finally, it is worth note that the animal model of silica-exposure used in the present study does not reproduce chronic silicosis. It does present, however, well-established functional and histological pulmonary changes 14 days after silica administration ([@B16]; [@B7]). Silica-induced chronic lung fibrosis usually results from long-lasting inflammation. Therefore, a better understanding of P2Y~12~ receptor role in acute inflammation would improve our knowledge about purinergic signaling in silicosis, opening new avenues to modify disease progression.

Conclusion {#S5}
==========

In conclusion, our results demonstrate that P2Y~12~ receptor is involved in silicosis, probably via its immunomodulatory effects. These findings corroborate and expand previous observations of purinergic signaling participation in silica-induced lung changes. Identification of novel mechanisms involved in disease progression may help in the development of efficient therapies.
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